1

2 SUPPLEMENTARY DATA

3

4 Supplemental methods

5

6 **Corticosterone immunoassay**

P2 mice were separated from their mother and placed on a heating pad for 5 min., then sacrificed and blood samples were quickly collected. Blood serum was separated by centrifugation (5,000 rpm, 20 min) and stored at -80°C. Serum corticosterone concentrations were measured with corticosterone ELISA kit (Enzo Life Sciences, Farmingdale, NY, USA) according to the manufacturer's instructions.

12

13 Supplemental figures

14

15 Supplemental figure 1.

A;C;E: Before/after graphs illustrating the latency to the first call measured upon exposure at 16 25°C (red dots) followed by 17°C (blue dots) in WT and in Magel2^{+/-p}. (A): At P1 : WT (25°C 17 vs 17°C) : 1.56±0.27 ln+1s vs 0.31±0.08 ln+1s, n=16; p=0.002. Magel2^{+/-p} (25°C vs 17°C) : 18 1.74 ±0.33 ln+1s vs 0.97±0.36 ln+1s, n=13; p=0.19. WT vs Magel2+/-p (25°C): 1.56±0.27 ln+1s, 19 n=16 vs 1.74±0.33 ln+1s; n=13; p>0.99. WT vs Magel2^{+/-p} (17°C): 0.31±0.08 ln+1s, n=16 20 vs0.97±0.36 ln+1s; n=13; p=0.19. (C): At P3: WT (25°C vs 17°C) : 2.08±0.32 ln+1s vs 21 22 1.19±0.27 ln+1s; n=15, p=0.04. Magel2^{+/-p} (25°C vs 17°C) : 2.5±0.38 ln+1s vs 3.24±0.46 ln+1s, n=16, p=0.07. WT vs Magel2^{+/-p} (25°C): 2.08±0.32 ln+1s, n=15 vs 2.5±0.38 ln+1s; n=16, 23 p=0.86. WT vs Magel2^{+/-p} (17°C): 1.19±0.27 ln+1s, n=15 vs 3.24±0.46 ln+1s; n=16, p=0.0005. 24 (E): At P6: WT (25°C vs 17°C) : 2.97±0.39 ln+1s vs 2.56±0.29 ln+1s, n=12, p=0.71.Magel2+/-p 25 (25°C vs 17°C): 2.33±0.42 ln+1s vs 3.90±0.39 ln+1s; n=12, p=0.0027. WT vs Magel2^{+/-p} (25°C) 26 : 2.97±0.39 ln+1s, n=12 vs 2.33±0.42 ln+1s; n=12, p=0.48. WT vs Magel2^{+/-p} (17°C) : 27

28 2.56±0.29 ln+1s, n=12 vs 3.90±0.39 ln+1s; n=12, p=0.033. Repeated-measures
29 (Temperature) Two-way ANOVA, Bonferroni's post-test.

B;D;F: Bar graphs comparing animals responsive rate of coolness-stimulated USV between
WT and Magel2^{+/-p} neonates from P1 to P6. At P1, WT: 87.5±8.5%, n=16 vs Magel2^{+/-p}:
58.82±12.3%; n=17; p<0.0001 (B). At P3, WT: 73.33±11.82%; n=15 vs Magel2^{+/-p}: 20±10.69%,
n=15; p<0.0001 (D). At P6, WT: 50±15.08%; n=12 vs Magel2^{+/-p}: 7.69±7.69%; n=13; p<0.0001
(F). Fisher's exact test.

G-H: Total number of calls over the age in WT (black lines) and *Magel2*^{+/-p} (orange lines) upon ambient (25°C) (G) and cool exposure (17°C) (H). At P2,17°C WT : 200.1±29.85; n=16 vs *Magel2*^{+/-p} : 105.2±23.7; n=17; p=0.0238. At P3, 17°C: WT: 201.6±35.31; n=16 vs *Magel2*^{+/-p} : 48.24±10.49; n=17; p<0.0001. Repeated-measures (age) Two-way ANOVA, Bonferroni's post-test.

40 Data are presented as mean±SEM.

41

42 Supplemental figure 2.

A: Experimental procedure for corticosterone assay. After room habituation, neonates are
separated from the dam, placed on a heating pad for 5 minutes and blood samples are
collected just before the USV recording.

B: Corticosterone plasma levels in female and male of WT and Magel2^{+/-p}. Males: WT:
12,974±6,711 ng/ml; n=6 vs Magel2^{+/-p}: 24,328±1,971 ng/ml; n=7, p=0.4740. Females: WT
19,983±4,425 ng/ml; n=7 vs Magel2^{+/-p}: 28,831±10,314 ng/ml; n=6, p=0.6723. Comparisons
between conditions revealed no significant difference. Two-way ANOVA, Bonferroni's posttest.

51 Data are presented as mean±SEM.

52

Supplemental Figure 3. Coolness reactivity in WT upon repeated or reverse temperature
 exposures

A-C: Before/after graphs illustrating the latency to the first call measured upon a repeated
exposure at 25°C (red dots) in new independent WT-only cohorts at P2 (B) and P3 (C).
Wilcoxon test.

58 **D-F**: Before/after graphs illustrating the latency to the first call measured upon exposure at

59 17°C (blue dots) followed by 25°C (red dots) in new independent WT-only cohorts at P2 (E)

60 and P3 (**F**). P2 WT (17°C vs 25°C): 0.61±0.0.18 ln+1 s vs 2.03±0.43 ln+1 s; n=14, p=0.0.0052;

61 P3 WT: 0.25±0.18 ln+1 s vs 1.40±1.05 ln+1 s; n=8, p=0.039. Wilcoxon test.

62 **G-H**: Bar graphs representing responsive rate of coolness-stimulated USV at P2 (**G**) and P3

63 (H). P2 WT: 25°C-17°C: 73.33±11.82 %, n=15; 25°C-25°C: 41.18±12.30 %, n=17; 17°C-25°C:

64 85.71±9.70 %, n=14. P3 WT: 25°C-17°C: 73.33±11.82 %, n=15; 25°C-25°C: 25.00±16.37 %,

65 n=8; 17°C-25°C: 66.67±16.67 %, n=9. Fisher's exact test.

66 Data are presented as mean±SEM.

67

68 Supplemental figure 4.

69 **A;C**: Before/after graphs represent the latency to the first call measured at 25°C (red squares)

70 and 17°C (blue squares) in Magel2^{+/-p} treated with OT (A): 2.03± 0.39 ln+1s vs 0.59±0.25 ln+1s;

n=13; p=0.0049), and AVP (C): 1.44±0.39 ln+1s vs 0.28±0.16 ln+1s; n=8; p=0.0156. Wilcoxon

72 test.

B;D: Bar graphs showing animals responsive rate of coolness-stimulated USV in Magel2^{+/-p}
untreated or treated with OT (B): 40±16.33 %; n=9 vs 76.92±12.16 %; n=13; p<0,0001), or
AVP (D): 75±16.37 %; n=8; p<0.0001. Fisher's exact test.

E: Latency to the first call measured at 25°C (red dots) and 17°C (blue dots) in vehicle (Veh) or TGOT-treated WT. Veh (25°C vs 17°C) : 1.48 ± 0.26 ln+1s vs 0.55 ± 0.13 ln+1s, n=15; p=0.0065. TGOT (25°C vs 17°C) : 1.71 ± 0.37 ln+1s vs 0.16 ± 0.05 ln+1s, n=11; p=0.0002. Veh vs TGOT (25°C): 1.48 ± 0.26 ln+1s, n= 15 vs 1.71 ± 0.37 ln+1s, n=11; p>0.99. Veh vs TGOT (17°C): 0.55 ± 0.13 ln+1s, n= 15 vs 0.16 ± 0.05 ln+1s, n=11; p=0.39. Repeated-measures (temperature) Two-way ANOVA, Bonferroni's post-test. F: Responsive rate of coolness stimulated USV in untreated WT compared with TGOT-treated
WT: 73.33±11.82 %; n=15 vs 81.82±12.20 %; n=11; p=0.2393. Fisher's exact test.

G: Total number of calls recorded during 5 minutes in Magel2^{+/-p} treated with vehicle
(41.3±16.48, n=10) and compared with OT (97.31±18.16%, n=13, p=0.45), or TGOT
(198.50±23.45 %, n=13, p=0.006), or AVP (205.30±44.03 %, n=10, p=0.0035). Kruskal-Wallis
test, Dunn's post-test.

- H: Total number of calls in untreated WT compared with TGOT-treated WT at 17°C:
 200.1±29.85; n=16 vs 255.5±39.92; n=11; p=0.5039. Mann Whitney test.
- 90 Data are presented as mean±SEM
- 91

92 Supplemental figure 5. Extracellular signal-regulated kinase (ERK) signaling after cool

93 exposure and oxytocin treatment

- 94 A-B: Representative Western blots of cerebral Erk and phosphorylated Erk (P-Erk) issued from
- 95 WT (A) and *Magel2*^{+/-p} (B) treated with vehicle (Veh) and exposed to 25 or 17°C.
- 96 **C-D**: Western-blots quantification: WT+Veh (25°C): 0.47±0.07 *vs* WT+Veh (17°C): 0.16±0.03;
- 97 n=6; p=0.0022 (C). Magel2^{+/-p}+Veh (25°C): 0.56±0.03; n=7 vs Magel2^{+/-p}+Veh (17°C):
- 98 0.58±0.07; n=5; p=0.7424 (D); Mann Whitney test.
- 99 E-F: Representative Western blots of cerebral Erk and phosphorylated Erk (P-Erk) issued from
- 100 WT (E) and *Magel*2^{+/-p} (F) treated with OT and exposed to 25 or 17°C exposed to 25 or 17°C.
- 101 **G-H**: Western-blots quantification: WT+OT (25°C): 1.32±0.11, n=5 vs WT+OT (17°C):
- 102 0.76±0.1; n=4; p=0.0317 (G). Magel2^{+/-p}+OT (25°C): 1.08±0.09; n=6 vs Magel2^{+/-p}+OT (17°C):
- 103 0.62±0.12; n=6; p=0.0087 (H); Mann Whitney tests.
- 104 Data are presented as mean±SEM.

105



Supplemental Figure 1



Supplemental Figure 2







D











G



Η





Supplemental Figure 3

A



Supplemental Figure 4



Supplemental Figure 5